Use of Δ5-androstene-3β-ol-7,17-dione in the treatment of lupus erythematosus
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Aug 2, 2005
Grant Date -
Mar 11, 2004
app pub date -
May 8, 2003
filing date -
Nov 19, 1997
priority date (Note) -
Expired
status (Latency Note)
Importance
Abstract
Lupus erythematosus can be treated by administering therapeutic amounts of Δ5-androstene-3β-ol-7,17-dione and metabolizable precursors thereof, such as Δ5-androstene-3b-acetoxy-7,17-dione, which are readily metabolized in vivo to Δ5-androstene-3β-ol-7,17-dione but are not appreciably metabolizable in vivo to androgens, estrogens or dehydroepiandrosterone. Such treatment can be prophylactic, ameliorative or curative in nature.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully